Return to ads
All categories


Posted by
Posting ads for 49 years
Sanofi-Aventis says data confirms Lantus safety By Sarah TurnerLONDON (MarketWatch) -- Shares of drugmaker Sanofi-Aventis (fr:san)(sny)dropped 8.2% in Paris on Friday.

"Commentary is circulating in the market that a safety issue may soon emerge for Lantus (long-acting insulin for diabetes), a major driver of revenue growth and profits at Sanofi-Aventis," noted analysts at Credit Suisse in a note.

"However, given the lack of any details, Credit Suisse Research prefers not to make any change yet to forecasts or valuation and retains an Outperform rating on the stock," they added.

A spokesman for Sanofi-Aventis said: "data from clinical studies involving over 70,000 patients as well as data from post-marketing surveillance covering 24 million patient years of experience confirms the safely profile of Lantus."
Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff